Meloxicam in Russia: 20 years together

2016 ◽  
Vol 88 (12) ◽  
pp. 149-158 ◽  
Author(s):  
A E Karateev ◽  
E N Nasonov
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Therapeutic Potential ◽  
Substantial Improvement ◽  
Brand Name ◽  
Good Tolerability ◽  
Extensive Experience ◽  
Spontaneous Reports ◽  
Anti Inflammatory ◽  
Low Incidence

Meloxicam is one of the most commonly used representatives of the group of nonsteroidal anti-inflammatory drugs prescribed in our country. It has been used in Russian clinical practice for 20 years and established itself as an effective and rather safe analgesic and anti-inflammatory medications. During this period almost 48 million packages of brand-name meloxicam have been sold; millions of people in our country have been successfully treated with this drug. During this period, there have been at least 29 Russian clinical trials of brand-name meloxicam, which covered 3,736 patients. In all the trials, meloxicam has demonstrated a good therapeutic potential (a substantial improvement in more than 75% of patients) and a low incidence of side effects, which averaged 6.4% (30.5% in the control groups). The good tolerability of brand-name meloxicam (Movalis) is confirmed by a total of 120 spontaneous reports of the adverse events due to this drug, which were sent to the Federal Service for Health Supervision in December 2008 to July 2015 (over the last 7 years). This number seems negligible (nearly 30 million packages) if the amount of meloxicam sold over the period is taken into account. Extensive experience in clinical practice with this drug and a wide series of national clinical trials support the good reputation of brand-name meloxicam among Russian physicians and patients. This review briefly gives the data of Russian and main foreign clinical trials of the therapeutic effect and safety of meloxicam.

scholarly journals Therapeutic potential of seaweeds

2021 ◽  
Vol 10 (5) ◽  
pp. 591
Author(s):  
Rajeev Goel ◽  
Tushar Saini ◽  
Binny Mahendru
Keyword(s):  
Clinical Trials ◽  
Therapeutic Potential ◽  
Biological Activities ◽  
Coastal Regions ◽  
Medicinal Compounds ◽  
Medicinal Properties ◽  
Low Incidence ◽  
Marine Nutrients

Seaweeds in general are known to contribute to the maintenance of health through their nutritional and medicinal properties and are served in soups and salads, cooked with grains, legumes or miso-soup broth, vegetable pies, stews and even consumed dried. The medicinal properties of seaweeds or vegetables have long been known in many cultures of people particularly those living in the coastal regions who are consuming these from centuries. Traditional Chinese dietotherapy (TCD) makes good use of natural marine nutrients and food to preserve health. Koreans wrap their bodies in seaweeds to get rid of deadly body toxins and Japanese who eat large quantities of seaweeds have very low incidence of cancers. The compounds with diverse biological activities such as antioxidant, antiviral, antifungal, antineoplastic, antimicrobial etc. have been isolated from the flora in the sea. A score of these bio-medicinal compounds are in different stages of clinical trials & analysis and are the focus of this article. 

scholarly journals An old friend: 25 years of meloxicam use in Russia.

2021 ◽  
Vol 59 (3) ◽  
pp. 302-315
Author(s):  
A. E. Karateev ◽  
E. L. Nasonov ◽  
E. Yu. Pogozheva ◽  
E. S. Filatova ◽  
V. N. Amirdzhanova ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Large Scale ◽  
Therapeutic Potential ◽  
Extensive Experience ◽  
Selective Blockade ◽  
Average Pain ◽  
Life Threatening ◽  
Low Incidence ◽  
High Level ◽  
Clinical Conditions

25 years ago, a new non-steroidal anti-inflammatory drug (NSAID) – meloxicam (Movalis®) – entered the clinical practice of our country. This drug was the first embodiment of the concept of selective blockade of cyclooxygenase 2 – the main pathway followed by pharmacological science to create a safe NSAID. A series of large-scale, well-organized randomized controlled trials and observational post-registration studies have confirmed the good efficacy and low incidence of adverse reactions (ADR) when using meloxicam. In our country, this drug has become one of the most popular analgesics. Until now, the original meloxicam has enjoyed a high level of trust among Russian doctors and patients. The reason for this is a long and very extensive experience in the clinical use of meloxicam (over 25 years, 63.7 million packages of the original drug were sold, which means that millions of our Russian citizens were treated with it), as well as a large number of clinical studies conducted by Russian scientists. So, to date, there are 36 Russian studies (n=8498) assessing the efficacy and safety of the original meloxicam in a variety of diseases and clinical conditions. Practically all of these studies have shown good therapeutic results: on average, pain relief is 50–75% of the initial level; good or excellent assessment of the drug effect in 70–80% of patients. The incidence of HP was on average 10.5±5.4%, and there were no serious life-threatening complications. This review briefly presents the data of Russian and major foreign clinical studies, which studied the therapeutic potential and safety of meloxicam.

Tea and health - part 2

2008 ◽  
Vol 291 ◽  
pp. 1-3
Keyword(s):  
Clinical Practice ◽  
Bone Health ◽  
Therapeutic Potential ◽  
Cns Disorders ◽  
Human Trials ◽  
Inflammatory Agent ◽  
Anti Inflammatory

In a nutshellThere is collectively quite a bit of evidence suggesting a therapeutic potential for tea and its polyphenols in areas such as prevention of CVD and degenerative CNS disorders, as an anti-infective and anti-inflammatory agent and to promote bone health.Further human trials are required to define the extent to which this is applicable in clinical practice.

scholarly journals COMBINED ACTION ANTIHYPERTENSIVE AGENT URAPIDIL: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE

2014 ◽  
Vol 13 (1) ◽  
pp. 57-63
Author(s):  
N. I. Gaponova ◽  
V. R. Abdrakhmanov ◽  
V. A. Kadyshev ◽  
A. Yu. Sokolov
Keyword(s):  
Blood Pressure ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Antihypertensive Agent ◽  
Antihypertensive Medication ◽  
Good Tolerability ◽  
Beneficial Effects ◽  
Action Mechanisms ◽  
Acute Elevation ◽  
Combined Action

The paper reviews the clinical practice potential of a combined action antihypertensive medication urapidil for the treatment of patients with acute elevation of blood pressure (BP) and confirms urapidil effectiveness and good tolerability. Urapidil action mechanisms, pharmacodynamics, and pharmacokinetics are discussed, together with the results of the key clinical trials which have demonstrated antihypertensive effectiveness and safety of this agent. Additional beneficial effects of urapidil, such as reduction of the increased pulmonary artery BP and improvement of bronchial conductivity, are also described.

scholarly journals Expected applications of the endometrial stem cells in clinical practice

2015 ◽  
Vol 64 (6) ◽  
pp. 68-77 ◽  
Author(s):  
Elena Olegovna Usoltceva ◽  
Alexander Mkrtichevich Gzgzyan ◽  
Liailia Kharryasovna Dzhemlikhanova ◽  
Dariko Aleksandrovna Niauri
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Clinical Practice ◽  
Cell Biology ◽  
Therapeutic Potential ◽  
Cell Engineering ◽  
Stem Cell Biology ◽  
Biological Basis ◽  
Endometrial Stem Cells

Recent findings in stem cell biology and cell engineering cannot be left without physicians’ attention. Endometrium as actively regenerating tissue represents also a source of endometrial stem cells. Endometrial stem cells have specific properties that distinguish them from other somatic stem cells. Endometrial stem cells have already shown their therapeutic efficiency and safety in a number of experimental and clinical trials. The biological basis of endometrial stem cells therapeutic potential and recent data on their use in clinical practice are discussed in the article.

Rationale for heparin treatment of colon cancer

2000 ◽  
Vol 20 (03) ◽  
pp. 136-142 ◽  
Author(s):  
D. L. Ornstein ◽  
L. R. Zacharski
Keyword(s):  
Clinical Trials ◽  
Substantial Improvement ◽  
Patients With Cancer ◽  
Coagulation Mechanism ◽  
Anticoagulant Drug ◽  
Cancer Outcome ◽  
Meta Analyses ◽  
Improvement In Survival ◽  
Spectrum Of Patients ◽  
To Receive

SummaryIt is widely known that the systemic blood coagulation mechanism is often activated in malignancy, leading to an increased incidence of vascular thromboses in patients with cancer. It is not widely appreciated, however, that products of the coagulation mechanism may also support tumor growth and dissemination. Interest in this approach to cancer therapy has surged recently because of mounting evidence that the familiar anticoagulant drug, heparin, may impede tumor progression. Heparin has the capacity to modify angiogenesis, growth factor and protease activity, immune function, cell proliferation and gene expression in ways that may block malignant dissemination. Clinical trials in which heparin has been administered to a broad spectrum of patients to prevent or treat thrombosis have unexpectedly shown improvement in survival in the subset of patients with malignancy entered to these studies. Meta-analyses of clinical trials comparing unfractionated (UF) versus low molecular weight (LMW) heparin treating venous thromboembolism suggest that there may be substantial improvement in cancer outcome in patients with malignancy randomized to receive LMW heparin. These findings provide a rationale for definitive clinical trials of LMW heparin in cancer, and the results of several such studies that are currently underway are awaited with interest.

Controlling Hypertension and Stroke Prevention – From Guideline to Clinical Practice

2011 ◽  
Vol 3 (1) ◽  
pp. 30
Author(s):  
Anding Xu ◽  
Zefeng Tan ◽  
◽  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Stroke Prevention ◽  
Modifiable Risk Factors ◽  
Cerebrovascular Events

Hypertension is the most important of the prevalent and modifiable risk factors for stroke. Based on evidence, blood pressure (BP) lowering is recommended in guidelines for the prevention of stroke. However, there are still some uncertainties in the guidelines for controlling BP and preventing stroke in patients with previous cerebrovascular events, such as the goal BP, who to treat and which class of BP-lowering drugs to use. This article discusses these questions by reviewing guidelines and corresponding clinical trials, with the aim of reducing the gap between guidelines and clinical practice.

Use of Polyhexanidine in Treating Chronic Wounds

2017 ◽  
Vol 68 (9) ◽  
pp. 2112-2113
Author(s):  
Laura Raducu ◽  
Andra Elena Balcangiu Stroescu ◽  
Iulia Ioana Stanescu ◽  
Maria Daniela Tanasescu ◽  
Cristina Nicoleta Cozma ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Chronic Wounds ◽  
Case Control Study ◽  
Case Control ◽  
Toxic Action ◽  
Good Tolerability ◽  
Long Period ◽  
Anti Inflammatory ◽  
Control Study

Chronic wounds have a long period of healing, being impeded by numerous factors, as infections. Polyhexanidine is a new broad spectrum antiseptic with non-toxic action which is used lately in wound cleaning solutions. A case control study was realized with two groups of patients treated with silver sulfodiazine and with polyhexanidine, the last group having an accelerated healing evolution. Besides the bactericide action, polyhexanidine has also no cytotoxicity, good tolerability and anti-inflammatory proprieties.

ANTIBODY-DRUG CONJUGATES FOR TARGETED CANCER THERAPY

2019 ◽  
Vol 65 (6) ◽  
pp. 777-784
Author(s):  
David Korman
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Gemtuzumab Ozogamicin ◽  
Brentuximab Vedotin ◽  
Cytostatic Agent ◽  
Cytostatic Agents ◽  
Drug Conjugates ◽  
Natural Substances ◽  
Intracellular Release ◽  
High Antitumor Activity

Monoclonal antibody (MAB) conjugates with cytostatic agents (ADC) are intended for selective delivery of a cytostatic agent to a tumor cell. Three ADC have been approved for clinical use (gemtuzumab ozogamicin, brentuximab vedotin, trastuzumab-DM1); a few dozens of other ADC are undergoing clinical trials. Several derivatives of natural substances (antibiotics and inhibitors of microtubules) having a high antitumor activity are used as cytostatic agents included in ADC. They are inapplicable in clinical practice as self-sustained drugs due to their considerable toxicity. Of great importance for the implementation of the ADC effect is the character of a linker connecting MAB with a cytostatic agent and ensuring selective intracellular release after ADC internalization. The structure, mechanisms of action, and the results of clinical trials of a number of ADC are considered here as an illustration (by way of example). The development of ADC can help introduce new effective cytostatic agents into clinical practice.

Sign in / Sign up

Export Citation Format

Share Document